Skip to main
TXG

10X Genomics (TXG) Stock Forecast & Price Target

10X Genomics (TXG) Analyst Ratings

Based on 11 analyst ratings
Hold
Strong Buy 18%
Buy 9%
Hold 73%
Sell 0%
Strong Sell 0%

Bulls say

10x Genomics is positioned for strong growth in the coming years with their innovative product offerings and a strong financial foundation. The company's recent Q2/26 production results may have missed estimates, but their Los Reyes PEA outlines a next avenue for growth and their FY2026 guidance is being reiterated. With a diversified geographic presence and continued expansion into new markets, 10x Genomics has a strong competitive advantage over new entrants in the genomics space. Additionally, the company's disciplined operating expense profile and expected growth in high-volume areas such as translational and clinical research demonstrate their ability to maintain profitability despite potential challenges.

Bears say

10x Genomics is facing production challenges as its Q2 AuEq production and sales fell below estimates due to lower-grade and lower-gold-recovery areas at Media Luna. Its recent quarter results align with the guidance of tracking towards the lower end of its reiterated 420-470 koz AuEq guidance range, requiring an increase in H2 grades to meet plans. Additionally, the company's revenues for the quarter grew 1% y/y but instrument revenues declined 36% y/y due to discounting, while operating expenses decreased 18% y/y.

10X Genomics (TXG) has been analyzed by 11 analysts, with a consensus rating of Hold. 18% of analysts recommend a Strong Buy, 9% recommend Buy, 73% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of 10X Genomics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About 10X Genomics (TXG) Forecast

Analysts have given 10X Genomics (TXG) a Hold based on their latest research and market trends.

According to 11 analysts, 10X Genomics (TXG) has a Hold consensus rating as of Jul 26, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $33.45, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $33.45, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

10X Genomics (TXG)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.